Evidence map›Paper›PMID 25473061›Full record

ArticleJournal of virology2015

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Annalisa Meola, Alexander W Tarr, Patrick England, Luke W Meredith, C Patrick McClure, Steven K H Foung, Jane A McKeating, Jonathan K Ball, Felix A Rey, Thomas Krey

Abstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Signatures of VNature communications · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Annalisa MeolaInstitut Pasteur, Unité de Virologie Structurale, Department Virologie, Paris, France CNRS UMR 3569, Paris, France.
Alexander W TarrSchool of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom Biomedical Research Unit in Gastrointestinal and Liver Diseases, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.
Patrick EnglandInstitut Pasteur, Plate-Forme de Biophysique des Macromolécules et de Leurs Interactions, Paris, France CNRS UMR 3528, Paris, France.
Luke W MeredithHepatitis C Research Group, Centre for Human Virology, University of Birmingham, Birmingham, United Kingdom.
C Patrick McClureSchool of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom Biomedical Research Unit in Gastrointestinal and Liver Diseases, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.
Steven K H FoungDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Jane A McKeatingHepatitis C Research Group, Centre for Human Virology, University of Birmingham, Birmingham, United Kingdom.
Jonathan K BallSchool of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom Biomedical Research Unit in Gastrointestinal and Liver Diseases, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.
Felix A ReyInstitut Pasteur, Unité de Virologie Structurale, Department Virologie, Paris, France CNRS UMR 3569, Paris, France.
Thomas KreyInstitut Pasteur, Unité de Virologie Structurale, Department Virologie, Paris, France CNRS UMR 3569, Paris, France tkrey@pasteur.fr.

Funding

Medical Research Council G0400802Medical Research Council G1100247
6 · The paper itself

Abstract

unlabelledNeutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of hepatitis C virus (HCV) infection. One conserved antigenic site (amino acids 412 to 423) is disordered in the reported E2 structure, but a synthetic peptide mimicking this site forms a β-hairpin in complex with three independent NAbs. Our structure of the same peptide in complex with NAb 3/11 demonstrates a strikingly different extended conformation. We also show that residues 412 to 423 are essential for virus entry but not for E2 folding. Together with the neutralizing capacity of the 3/11 Fab fragment, this indicates an unexpected structural flexibility within this epitope. NAbs 3/11 and AP33 (recognizing the extended and β-hairpin conformations, respectively) display similar neutralizing activities despite converse binding kinetics. Our results suggest that HCV utilizes conformational flexibility as an immune evasion strategy, contributing to the limited immunogenicity of this epitope in patients, similar to the conformational flexibility described for other enveloped and nonenveloped viruses. IMPORTANCE: Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), and neutralizing antibodies play an important role in controlling the replication of this major human pathogen. We show here that one of the most conserved antigenic sites within the major glycoprotein E2 (amino acids 412 to 423), which is disordered in the recently reported crystal structure of an E2 core fragment, can adopt different conformations in the context of the infectious virus particle. Recombinant Fab fragments recognizing different conformations of this antigenic site have similar neutralization activities in spite of converse kinetic binding parameters. Of note, an antibody response targeting this antigenic region is less frequent than those targeting other more immunogenic regions in E2. Our results suggest that the observed conformational flexibility in this conserved antigenic region contributes to the evasion of the humoral host immune response, facilitating chronicity and the viral spread of HCV within an infected individual.

Indexed as

Antibodies, NeutralizingEpitopesHepacivirusHepatitis C AntibodiesHumansImmune EvasionModels, MolecularProtein BindingProtein ConformationViral Envelope ProteinsAntibodies, NeutralizingEpitopesglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesViral Envelope Proteins

Identifiers

PMID25473061
PMCPMC4338873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.